497 related articles for article (PubMed ID: 15620822)
1. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
2. Visceral leishmaniasis during childhood in southern Greece.
Maltezou HC; Siafas C; Mavrikou M; Spyridis P; Stavrinadis C; Karpathios T; Kafetzis DA
Clin Infect Dis; 2000 Nov; 31(5):1139-43. PubMed ID: 11073742
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children.
Apa H; Devrim İ; Bayram N; Deveci R; Demir-Özek G; Cartı ÖU
Turk J Pediatr; 2013; 55(4):378-83. PubMed ID: 24292030
[TBL] [Abstract][Full Text] [Related]
4. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice.
Gradoni L; Davidson RN; Orsini S; Betto P; Giambenedetti M
J Drug Target; 1993; 1(4):311-6. PubMed ID: 8069573
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
6. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
Dilber E; Erduran E; Işik Y
Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Mediterranean visceral leishmaniasis.
Gradoni L; Bryceson A; Desjeux P
Bull World Health Organ; 1995; 73(2):191-7. PubMed ID: 7743590
[TBL] [Abstract][Full Text] [Related]
8. Visceral leishmaniasis treatment, Italy.
Gradoni L; Gramiccia M; Scalone A
Emerg Infect Dis; 2003 Dec; 9(12):1617-20. PubMed ID: 14720406
[TBL] [Abstract][Full Text] [Related]
9. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
[TBL] [Abstract][Full Text] [Related]
12. Pediatric visceral leishmaniasis in southern France.
Minodier P; Piarroux R; Garnier JM; Unal D; Perrimond H; Dumon H
Pediatr Infect Dis J; 1998 Aug; 17(8):701-4. PubMed ID: 9726344
[TBL] [Abstract][Full Text] [Related]
13. Mediterranean visceral leishmaniasis in pregnancy.
Gradoni L; Gaeta GB; Pellizzer G; Maisto A; Scalone A
Scand J Infect Dis; 1994; 26(5):627-9. PubMed ID: 7855563
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
[TBL] [Abstract][Full Text] [Related]
15. [Visceral leishmaniasis: new drugs].
Minodier P; Robert S; Retornaz K; Garnier JM
Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
[TBL] [Abstract][Full Text] [Related]
17. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
Minodier P; Retornaz K; Horelt A; Garnier JM
Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
[TBL] [Abstract][Full Text] [Related]
18. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience.
Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S
J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of infantile visceral leishmaniasis].
Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
[TBL] [Abstract][Full Text] [Related]
20. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]